Ga direct naar de inhoud

Ga direct naar de navigatie

Uitgave van

Archief voor de categorie ‘Clinical trial(s)’

Breakthrough study could revolutionise MS treatment

The results of a study from the University of California, San Francisco will be welcomed with a certain excitement from all quarters, given that it seems to show the repair of myelin damaged by multiple sclerosis (MS) and, to add to the news, is achieved through the use of a generic allergy medication.

Bron: Pharmafile Meer lezen »

Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of biosimilar to Humira

Boehringer Ingelheim has announced results from the pivotal Phase III VOLTAIRE®-RA(1) study, confirming that its adalimumab biosimilar candidate BI 695501 and HUMIRA®* have similar efficacy, safety and immunogenicity in patients with moderately-to-severely active rheumatoid arthritis. The 24 week results will be presented at the Annual European Congress of Rheumatology (EULAR 2017) in Madrid.

Bron: World Pharma News Meer lezen »

Type 1 Diabetes Reversal May be Possible with TB Vaccine

Faustman’s team is preparing for a 5-year, 150-person Phase 2 trial to investigate the potential for repeat BCG vaccination to improve type 1 diabetes in adults with existing disease. According to data from a recent Phase 1 trial directed by the Massachusetts General Hospital Immunobiology Laboratory, the vaccine bacillus Calmette-Guérin (BCG) may have the potential to […]

Bron: Monthly Prescribing Reference (MPR): Drug News Meer lezen »

Twee fase-3 onderzoeken met sotagliflozine bij type 1 diabetespatiënten bieden perspectief

Sotagliflozin (SOTA) is een orale remmer van zowel SGLT-1 als SGLT-2. Al eerder is aangetoond dat het een effectief en goed getolereerd middel is om de bloedglucose in type 1 en type 2 diabetespatiënten te verlagen. Uit twee recente fase-3 studies in type 1 diabetespatiënten blijkt SOTA als toevoeging aan insuline de glykemische controle te […]

Bron: mednet nieuws Meer lezen »

Sanofi-Regeneron’s Praluent cuts cholesterol in Odyssey trials

France’s Sanofi and partner Regeneron Pharmaceuticals said on Sunday their anti-cholesterol drug Praluent recorded positive results in its first dedicated studies involving patients with diabetes and high cholesterol. Praluent significantly reduced low-density lipoprotein cholesterol in two phase 3b/4 Odyssey trials, the companies said in a joint statement.

Bron: Reuters Meer lezen »

Novartis touts new T-cell therapy data in race for FDA approval

Novartis on Wednesday touted new data from its T-cell therapy CTL019, saying it is on a par with results of experimental molecules from Kite Pharma and Juno Therapeutics that also target aggressive blood cancers.

Bron: Reuters Meer lezen »

Immuno-oncology upset in bladder cancer

  Roche and Genentech’s checkpoint inhibitor atezolizumab did not improve overall survival in a confirmatory phase III trial in patients with advanced bladder cancer. The FDA granted accelerated approval to the anti-programmed cell death protein 1 ligand 1 (PDL1) antibody for this indication in 2016

Bron: Nature Reviews Drug Discovery Meer lezen »

Swiss biotech NLS Pharma’s ADHD drug succeeds in mid-stage study

Swiss biotech NLS Pharma AG said on Wednesday mid-stage trial data showed that its drug to treat attention deficit hyperactivity disorder (ADHD) greatly reduced symptoms in adults, paving the way for a late-stage trial.

Bron: Reuters Meer lezen »

AstraZeneca phase IIIb/IV EXSCEL of Bydureon meets primary endpoint

AstraZeneca has announced top─line results from the phase IIIb/IV EXSCEL (EXenatide Study of Cardiovascular Event Lowering) trial. The trial compared the effect of once─weekly Bydureon (exenatide extended─release) versus placebo.

Bron: Pharma Biz Meer lezen »

Shire’s angioedema drug succeeds in late-stage study

Shire Plc said successful late-stage data on its long-acting drug for hereditary angioedema would form the basis of a U.S. marketing application for the treatment. U.S.-listed shares of company, which already sells a number of hereditary angioedema (HAE) treatments, were up about 6 percent at $193.15 before the bell on Thursday.

Bron: Reuters Meer lezen »

« Oudere artikelen |